Latest news for Lilium (OTC:LILMF) Stock

Lilium NV creates a sustainable and accessible mode of high-speed, regional transportation. Using the 7-Seater Lilium Jet, an electric vertical take-off and landing jet, offering leading capacity, low noise and high performance, it is building a transport network and service for people and goods.

Lilium NV

News

Guidance

MRVI

Maravai LifeSciences Expects To Report Total 2024 Revenue Near The Mid-point Of Prior Guidance Range Of $255M - $265M, Est $259.773M

WIIM

Penguin Solutions, Inc. - Ordinary Shares

PENG

Penguin Solutions shares are trading higher after the company reported better-than-expected Q1 financial results.

Saratoga Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) reported quarterly earnings of $0.90 per share which missed the analyst consensus estimate of $0.94 by 4.26 percent. The company reported quarterly sales of $35.88 million which beat the analyst consensus estimate of $35.26 million by 1.77 percent. This is a 1.27 percent decrease over sales of $36.34 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Saratoga Investment Q3 2025 Adj EPS $0.90 Misses $0.94 Estimate, Sales $35.88M Beat $35.26M Estimate

Press Conference Delayed to Pursue Key Deal
VANCOUVER, BC, Jan. 8, 2025 /PRNewswire/ -- Siyata Mobile Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>)&nbsp;("Siyata" or the "Company"), a global developer and vendor of Push-to-Talk over Cellular (PoC) handsets and accessories,&nbsp;announces that it has postponed its upcoming press conference, originally set for January 9, 2025, to focus on advancing an immediate business opportunity. The press conference will be rescheduled to later this month, with the new date to be announced shortly.
In addition, the Company announced that it has received an order from a major transit authority for over two thousand SD7 handsets and accessories to replace the authority's mobile land radios. The order is expected to be delivered in the first quarter of 2025.

Contracts

SYTA

Siyata Mobile Delays Press Conference Originally Set For January 9, 2025 To Focus On Key Deal; Receives Order For 2,000 SD7 Handsets From Transit Authority, Delivery Expected Q1 2025

RBC Capital analyst Darko Mihelic upgrades Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) from Sector Perform to Outperform and raises the price target from C$133 to C$161.

Upgrades

Price Target

Analyst Ratings

TSX:BMO

RBC Capital Upgrades Bank of Montreal to Outperform, Raises Price Target to C$161

DBVT

DBV Technologies shares are trading higher after the company announced 3-year results from its IPITOPE Phase 3 open-label extension study.

Penguin Solutions Affirms FY25 Outlook; EPS At $1.30 - $1.70 (Est $1.67), Net Sales Growth At 15% YoY +/- 5%

- Targeted enrollment of 168 RRMS patients achieved in December 2024 - The last patient is expected to complete the trial in the third quarter of 2025
Contineum Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting multiple sclerosis (RRMS).
The Phase 2, randomized, double-blind, placebo-controlled, multi-center, proof-of-concept trial of PIPE-307 will assess safety and efficacy in RRMS patients. The trial is designed to measure multiple clinical and imaging endpoints sensitive to changes in remyelination in RRMS. Contineum anticipates that the last patient will complete the PIPE-307 VISTA trial in the third quarter of 2025. More information on this trial can be found at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06083753&amp;esheet=54175164&amp;newsitemid=20250108107473&amp;lan=en-US&amp;anchor=https%3A%2F%2Fclinicaltrials.gov&amp;index=1&amp;md5=e66f6e6c8044a6a82bdad4ef24e1e138">https://clinicaltrials.gov</a> (NCT06083753).

Biotech

General

CTNM

Contineum Therapeutics Completes Enrollment In Phase 2 PIPE-307 VISTA Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis; The Last Patient Is Expected To Complete The Trial In Q3 2025

Dyne Therapeutics To Release New Clinical Data From Phase 1/2 ACHIEVE Trial On January 10, 2025; Investor Conference Call And Webcast Scheduled For 8:00 AM ET

RBC Capital analyst Darko Mihelic upgrades Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) from Sector Perform to Outperform and raises the price target from C$97 to C$103.

TSX:CM

RBC Capital Upgrades Canadian Imperial Bank to Outperform, Raises Price Target to C$103

<ul>
<li>EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN&#xAE; Peanut patch in toddlers 1 – 3 years through 36 months</li>
<li>68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12</li>
<li>No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE &nbsp;&nbsp;</li>
<li>DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FDA</li>
<li>DBV to highlight these data in multiple abstract presentations at the Eastern Food Allergy &amp; Comorbidity Conference, January 9-12, in Palm Beach, Florida
<ul>
<li>Company to host investor webcast today at 5:00pm ET</li>
</ul>
</li>
</ul>

DBV Technologies Announces  3-Year Results from EPITOPE Phase 3 Open-Label Extension Study; Data Provided Support That Continued Treatment With VIASKIN Peanut Showed Improveemntn Through 36 Months Of Treatment Across All Efficacy Parameters

NPCE

NeuroPace Sees Prelim. Q4 Revenue $21M-$21.5M vs $20.909M, Sees Prelim. 2024 Revenue $79.4M-$79.9M vs $79.183M Est.

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.15 by 40 percent. The company reported quarterly sales of $69.10 million which missed the analyst consensus estimate of $70.15 million by 1.50 percent. This is a 1.02 percent increase over sales of $68.40 million the same period last year.

Franklin Covey Q1 2025 GAAP EPS $0.09 Misses $0.15 Estimate, Sales $69.10M Miss $70.15M Estimate

Minutes from the Federal Reserve's December meeting released on Wednesday show officials are uncertain about the path of future rate cuts, as President-elect Donald Trump's policies and how they could <a href="https://www.benzinga.com/news/econ-s/25/01/42884303/fed-minutes-reveal-inflation-jitters-policymakers-signal-slower-interest-rate-easing-path-ahead">affect inflation remain unknown.</a><a href="https://www.benzinga.com/news/econ-s/25/01/42884303/fed-minutes-reveal-inflation-jitters-policymakers-signal-slower-interest-rate-easing-path-ahead"> </a>
Expert Ideas: Jeffrey Roach, chief economist for LPL Financial, highlighted the Federal Reserve's use of the word "uncertain or a derivation thereof" 12 times throughout the official record from the Federal Open Market Committee and noted that participants find it increasingly difficult to map out a path for interest rates in the face of uncertainty.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/01/42878466/wildfire-rips-through-las-pacific-palisades-neighborhood-3000-acres-burned-30000-evacuated-homes-destroyed">Wildfire Rips Through LA&#8217;s Pacific Palisades Neighborhood Destroying Homes: 3,000 Acres Burned As 30,000 Residents Evacuate&nbsp;</a>
Roach also pointed to "surprising" comments indicating Fed officials think "the strength of economic activity was unlikely to be a source of upward inflation pressures."&nbsp;
He also referred to industry data that suggests hiring plans are softening and said markets could "get choppy" if Friday's payroll report surprises to the downside.&nbsp;
Larry Tentarelli, chief technical strategist for Blue Chip Daily Trend Report, projects the Fed to stay "on pause" for the next few meetings given ongoing sticky inflation and continued strength in the job market.&nbsp;
However, he also said there is "possible risk to the upside at 5.00% for 10-year yields" if Friday's nonfarm payrolls report comes in above forecast.&nbsp;
"Our view for investors is they should expect no rate cuts in Q1 2025 and 10-year US Treasury yields in the 4.50 to 5.00% range at least for the first quarter of 2025," Tentarelli wrote.&nbsp;
Markets React: Markets are ended Wednesday mixed following the release of the Fed minutes. The Dow Jones Industrial Average was up 0.25% and the S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) also finished marginally higher on the session. The tech-heavy Nasdaq 100, tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), was down 0.06% at the closing bell. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally&nbsp;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Government

Broad U.S. Equity ETFs

Federal Reserve

ETFs

'No Rate Cuts In Q1 2025,' Strategist Says After Fed's December Minutes

<h3>Gainers</h3>
<ul>
<li>Airgain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRG#NASDAQ">AIRG</a>) stock rose 20.7% to $7.98 during Wednesday's pre-market session. The company's market cap stands at $90.5 million. </li>
<li>VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) shares rose 7.84% to $1.65. The market value of their outstanding shares is at $17.3 million. </li>
<li>Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) stock moved upwards by 6.32% to $7.56. The market value of their outstanding shares is at $295.6 million. </li>
<li>SatixFy Communications (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SATX#AMEX">SATX</a>) stock increased by 5.74% to $1.84. The company's market cap stands at $153.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DatChat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) stock fell 58.0% to $3.75 during Wednesday's pre-market session. The market value of their outstanding shares is at $11.2 million. </li>
<li>XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) stock decreased by 47.46% to $0.06. The market value of their outstanding shares is at $17.6 million. </li>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) stock decreased by 33.05% to $11.71. The company's market cap stands at $1.5 billion. </li>
<li>D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) stock decreased by 32.99% to $6.4. The company's market cap stands at $1.7 billion. </li>
<li>AmpliTech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) shares fell 30.61% to $2.52. The company's market cap stands at $49.5 million. </li>
<li>Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) stock fell 30.46% to $12.79. The market value of their outstanding shares is at $3.5 billion. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIRG

AMPG

DATS

DOMO

QBTS

QUBT

RGTI

SatixFy Communications Ltd. Ordinary Share

SATX

VRME

XTIA

10 Information Technology Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares increased by 9.5% to $0.75 during Wednesday's pre-market session. The market value of their outstanding shares is at $11.9 million. </li>
<li>Tokyo Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) shares rose 8.4% to $3.74. The company's market cap stands at $157.9 million. </li>
<li>Cato (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATO#NYSE">CATO</a>) stock rose 7.81% to $4.0. The company's market cap stands at $82.1 million. </li>
<li>eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) stock moved upwards by 7.48% to $67.9. The market value of their outstanding shares is at $32.5 billion. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) shares increased by 6.01% to $8.29. The market value of their outstanding shares is at $22.4 million. </li>
<li>Jinxin Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMI#NASDAQ">NAMI</a>) stock increased by 5.88% to $4.32. The company's market cap stands at $276.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares declined by 28.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $15.3 million. </li>
<li>SRIVARU Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares decreased by 19.41% to $0.07. The company's market cap stands at $37.1 million. </li>
<li>Fenbo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEBO#NASDAQ">FEBO</a>) shares fell 14.2% to $1.86. The company's market cap stands at $20.5 million. </li>
<li>Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) shares fell 13.22% to $12.41. The company's market cap stands at $400.6 million. </li>
<li>Sacks Parente Golf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPGC#NASDAQ">SPGC</a>) stock declined by 12.05% to $0.39. The company's market cap stands at $3.4 million. </li>
<li>Unifi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) shares decreased by 10.44% to $5.41. The company's market cap stands at $98.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALUR

CATO

EBAY

FEBO

NAMI

RIME

SPGC

SVMH

TKLF

XPOF

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

Updated Cash Runway Guidance
As of December 31, 2024, the Company had cash resources of approximately $324 million (unaudited), consisting of cash, cash equivalents, and marketable securities, not including a $25 million milestone payment earned in 4Q-2024 from Jazz Pharmaceuticals which is expected to be received in 1Q-2025. Based on current operating plans and assuming receipt of certain anticipated regulatory milestones, we continue to expect our existing cash resources, when combined with such anticipated milestone payments, will enable us to fund planned operations into 2H-2027.

ZYME

Zymeworks Expects $324M Cash Resources, Plus $25M Milestone, To Fund Operations Into 2H-2027

<h3>Gainers</h3>
<ul>
<li>Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares moved upwards by 263.0% to $5.99 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Accolade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) shares moved upwards by 105.67% to $6.89. The market value of their outstanding shares is at $554.9 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock rose 82.56% to $1.99. The market value of their outstanding shares is at $8.9 million. </li>
<li>Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) stock moved upwards by 59.31% to $12.57. The company's market cap stands at $1.7 billion. </li>
<li>Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) shares moved upwards by 33.22% to $4.09. The market value of their outstanding shares is at $469.7 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock increased by 30.21% to $0.12. The company's market cap stands at $14.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) shares declined by 50.3% to $8.8 during Wednesday's pre-market session. The company's market cap stands at $132.0 million. </li>
<li>AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) stock decreased by 26.75% to $10.3. The market value of their outstanding shares is at $270.0 million. </li>
<li>DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) shares fell 26.15% to $1.13. The market value of their outstanding shares is at $38.5 million. </li>
<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) stock fell 21.5% to $1.79. The market value of their outstanding shares is at $12.3 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares decreased by 19.89% to $2.8. The company's market cap stands at $492.5 million. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares declined by 18.38% to $2.31. The market value of their outstanding shares is at $39.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

ACCD

DRIO

HOTH

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

MBOT

RCEL

SANA

SILO

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) shares increased by 12.0% to $2.8 during Wednesday's pre-market session. The market value of their outstanding shares is at $151.7 million. </li>
<li>Caravelle Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock increased by 10.16% to $3.87. The market value of their outstanding shares is at $215.7 million. </li>
<li>Tigo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) stock increased by 9.06% to $1.08. The market value of their outstanding shares is at $65.6 million. </li>
<li>AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) stock moved upwards by 8.5% to $67.0. The market value of their outstanding shares is at $2.4 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) stock moved upwards by 8.47% to $3.84. The company's market cap stands at $97.7 million. </li>
<li>Performance Shipping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSHG#NASDAQ">PSHG</a>) stock increased by 7.42% to $1.88. The company's market cap stands at $23.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock declined by 29.8% to $1.96 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.1 million. </li>
<li>Simpple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) stock fell 16.22% to $1.24. The market value of their outstanding shares is at $20.1 million. </li>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) shares decreased by 13.75% to $0.27. The market value of their outstanding shares is at $5.3 million. </li>
<li>SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) stock fell 13.18% to $1.52. The company's market cap stands at $543.3 million. </li>
<li>Mynaric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) shares declined by 11.47% to $0.67. The company's market cap stands at $16.8 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares declined by 11.44% to $0.58. The company's market cap stands at $2.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

BAER

EFSH

EHGO

HTCO

MYNA

PSHG

SGBX

SPPL

TYGO

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.39 by 25.64 percent. This is a 104.17 percent increase over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $341.10 million which beat the analyst consensus estimate of $320.75 million by 6.35 percent. This is a 24.38 percent increase over sales of $274.25 million the same period last year.

Penguin Solutions Q1 2025 Adj EPS $0.49 Beats $0.39 Estimate, Sales $341.10M Beat $320.75M Estimate

Lilium (LILMF) has released an update. Lilium N.V. has initiated insolvency proceedings in Germany, appointing a preliminary insolvency administrat...

Lilium Initiates Insolvency Proceedings Amid Board Changes

Eve Holdings Remains A Speculative Buy Even With Certification Delays On eVTOL

Lilium (LILMF) has released an update. Lilium GmbH is making significant strides with its electric aircraft program, securing a sales agreement for...

Lilium Gains Traction with New Jet Orders Amid Restructuring

Lilium ( ($LILMF) ) has provided an announcement. Lilium N.V. has announced that its key subsidiaries, Lilium GmbH and Lilium eAircraft GmbH, have ...

Lilium N.V. Subsidiaries File for Insolvency Amid Restructuring Efforts

Air taxi startup Lilium finds a buyer, stock skyrockets 268%

EVEX

LILMF

LILWF

Legal

Press Releases

Lilium N.V. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 6, 2025 to Discuss Your Rights – LILMF

LILM DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Lilium N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 6 Deadline in Securities Class Action – LILM, LILMF

Small Cap

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 6, 2025 in Lilium N.V. Lawsuit - LILMF

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Lilium N.V.(LILMF) Shareholders

LILMF LAWSUIT ALERT: Levi & Korsinsky Notifies Lilium N.V. Investors of a Class Action Lawsuit and Upcoming Deadline

LILM DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Lilium N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 6 Deadline in Securities Class Action – LILM, LILMF

LILM, LILMF Deadline: LILM, LILMF Investors with Losses in Excess of $100K Have Opportunity to Lead Lilium N.V. Securities Fraud Lawsuit

LILM, LILMF Deadline: Rosen Law Firm Urges Lilium N.V. (NASDAQ: LILM) (OTC: LILMF) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Class Action Filed Against Lilium N.V. (LILMF) - January 6, 2025 Deadline to Join - Contact The Gross Law Firm

LILM DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Lilium N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 6 Deadline in Securities Class Action – LILM, LILMF

LILM

Lilium

Comments

Lilium

News

Latest news for Lilium (OTC:LILMF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga